SCHEMBL22174233

SCHEMBL22174233

C=CC(=O)N1CC(Oc2ccc(OC)cc2)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TET3 O43151 2/20 0.51
KMT2A Q03164 2/20 0.51
FBXL19 Q6PCT2 2/20 0.51
CXXC5 Q7LFL8 2/20 0.51
TET1 Q8NFU7 2/20 0.51
KDM2B Q8NHM5 2/20 0.51
CXXC4 Q9H2H0 2/20 0.51
KDM2A Q9Y2K7 2/20 0.51
EGFR P00533 5/20 0.46
ITK Q08881 1/20 0.46
ERBB2 P04626 3/20 0.46
RYR2 Q92736 1/20 0.45
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KCNH2 Q12809 3/20 0.43
MCHR1 Q99705 3/20 0.43
TGM2 P21980 1/20 0.43
EPHX2 P34913 1/20 0.43
BTK Q06187 1/20 0.42
GRIN1 Q05586 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26217925 0.88 ACHE (0.46) TET3KMT2AFBXL19CXXC5TET1
SCHEMBL22446321 0.87 KMT2A (0.56) TET3KMT2AFBXL19CXXC5TET1
SCHEMBL22174135 0.86 EGFR (0.50) EGFRITKERBB2RYR2EPHX2
SCHEMBL22174252 0.85 EGFR (0.47) TET3KMT2AFBXL19CXXC5KDM2B
SCHEMBL26216582 0.84 ADRB2 (0.48) TET3KMT2AFBXL19CXXC5TET1
SCHEMBL22173964 0.83 TET3 (0.53) TET3KMT2AFBXL19CXXC5TET1
SCHEMBL22174132 0.83 GPR119 (0.50) KMT2AEGFRERBB2MAPTSMN1; SMN2
SCHEMBL1196748 0.83 KCNH2 (0.46) KMT2AMAPTSMN1; SMN2KCNH2MCHR1
SCHEMBL22174136 0.82 NAAA (0.51) KMT2AEGFRERBB2SMN1; SMN2EPHX2
SCHEMBL24168592 0.81 TEAD1 (0.56) EGFRERBB2EPHX2BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11771689-B2 Cereblon modulators and uses thereof VIVIDION THERAPEUTICS, INC. (US) 2023-10-03 US disclosed
US-11771689-B2 Cereblon modulators and uses thereof VIVIDION THERAPEUTICS, INC. (US) 2023-10-03 US disclosed
US-20220298213-A1 IN VIVO ENGINEERED CEREBLON PROTEIN VIVIDION THERAPEUTICS, INC. 2022-09-22 US disclosed
US-10869860-B2 Cereblon modulators and uses thereof VIVIDION THERAPEUTICS, INC. (US) 2020-12-22 US disclosed
US-20200216507-A1 IN VIVO ENGINEERED CEREBLON PROTEIN VIVIDION THERAPEUTICS, INC. 2020-07-09 US disclosed
US-20200206201-A1 CEREBLON MODULATORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2020-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298213-A1 IN VIVO ENGINEERED CEREBLON PROTEIN CRBN, CDR2, DCUN1D4 TET3 666/4885KMT2A 607/4885FBXL19 247/4885
US-20200216507-A1 IN VIVO ENGINEERED CEREBLON PROTEIN CRBN, CDR2, DCUN1D4 TET3 666/4885KMT2A 607/4885FBXL19 247/4885
US-11771689-B2 Cereblon modulators and uses thereof CRBN, CBFB, CNN2 TET3 4521/4885KMT2A 3580/4885FBXL19 3394/4885
US-10869860-B2 Cereblon modulators and uses thereof CRBN, CBFB, CNN2 TET3 4521/4885KMT2A 3580/4885FBXL19 3394/4885
US-20200206201-A1 CEREBLON MODULATORS AND USES THEREOF CRBN, CBFB, CNN2 TET3 4521/4885KMT2A 3580/4885FBXL19 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.